Acrivon CEO to Discuss Pipeline Progress at Cantor Healthcare Conference
Event summary
- Acrivon Therapeutics CEO Peter Blume-Jensen to participate in fireside chat at 2026 Cantor Global Healthcare Conference on September 9, 2026.
- Company advancing lead program ACR-368 in potentially registrational Phase 2 trial for endometrial cancer with FDA Fast Track designation.
- ACR-2316 Phase 1/2 study showing durable clinical activity in lung cancer patients, with some on treatment for over a year.
- Early IND-enabling studies underway for potential first-in-class CDK11 inhibitors.
The big picture
Acrivon's conference appearance comes as precision oncology faces increasing competition from AI-driven drug discovery platforms. The company's proprietary AP3 platform represents a potential differentiator in identifying novel targets and designing differentiated compounds. Success in advancing multiple programs simultaneously would position Acrivon as a key player in the next wave of targeted cancer therapies.
What we're watching
- Clinical Validation
- Whether ACR-2316's durable responses in lung cancer can translate into broader tumor type efficacy.
- Regulatory Momentum
- The pace at which ACR-368 advances through potentially registrational Phase 2 trial.
- Pipeline Progression
- How quickly Acrivon can move CDK11 programs from early studies to clinical stages.
Related topics